PT-141 for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

PT-141 for Health & Longevity

Created on 10/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

PT-141 is a prescription peptide medication for low sexual desire, injected before sexual activity, that acts on brain pathways. In women before menopause with distressing low desire, trials show modestly more desire and less distress, but not more satisfying encounters. Evidence in men is limited. Nausea is common, blood pressure rises briefly, and frequent use can darken skin. No study links it to longer life; its relevance is sexual well-being. (Full Review)

Protocol

Approved regimen (women)
1.75 mg subcutaneous
Autoinjector into abdomen or thigh, at least 45 minutes before activity
Off-label regimen (men)
1–2 mg subcutaneous
1 mg start; no more than every 3–4 days, per one urology clinic that sells PT-141 therapy
Single versus split dosing
One single dose per occasion
Second dose within 24 hours excluded by the label; split dosing unstudied
Time to effect
Sexual desire, single dose
45 min before activity
Dosing at least 45 minutes ahead; desire effects may last up to 24 hours
Sexual desire, repeated use
Week 4
Earliest trial timepoint; the label allows 8 weeks to judge benefit
Appetite and body weight
16 days
Lower weight than placebo with dosing one to three times daily in women with obesity

Benefits

Contraindications
  • Uncontrolled hypertension or known cardiovascular disease (contraindicated)
  • High cardiovascular risk (not recommended)
  • Pregnancy or suspected pregnancy
  • Oral naltrexone for alcohol or opioid dependence
  • Severe kidney (eGFR <30 mL/min/1.73 m²) or liver (Child-Pugh C) impairment: use with caution only
  • Personal history of melanoma or atypical moles (theoretical)
    •
Key Interactions
  • Time-critical oral drugs (antibiotics such as amoxicillin, doxycycline): Avoid (label)
  • NSAIDs (pain relievers: indomethacin, ibuprofen, naproxen): Caution
  • Other melanocortin-receptor activators (melanotan II, setmelanotide): Avoid (theoretical)
  • Antihypertensives (beta-blockers: metoprolol; calcium-channel blockers: amlodipine): Monitor (theoretical)
  • PDE5 inhibitors (sildenafil, tadalafil): Monitor
  • GLP-1 receptor agonists (drugs that curb appetite: semaglutide, tirzepatide): Monitor (theoretical)
  • Decongestants and stimulants (pseudoephedrine, phenylephrine, high-dose caffeine): Caution (theoretical)
  • Blood-pressure-raising supplements (yohimbine, synephrine, licorice root): Caution (theoretical)
  • Sun exposure and tanning beds: Caution (theoretical)
  • Ondansetron (anti-nausea drug): No benefit
  • Alcohol: No interaction
    •

Risk & Side Effects

  • High: Nausea and vomiting
    •
  • Medium: Flushing; headache; transient blood-pressure rise and heart-rate drop; patchy darkening of skin and gums; injection-site reactions
    •
  • Low: Acute hepatitis; new or changing moles and melanoma; prolonged, painful erection
    •
  • Speculative: Fetal harm during pregnancy
    •

Monitoring

Marker Target Why
Blood pressure Below 120/80 mmHg Safety check: uncontrolled hypertension stops use
Resting heart rate 60–100 beats/min Safety check: excess slowing changes use, especially with beta-blockers
Pregnancy test (hCG) Negative Safety check: positive result stops use
Skin and mole examination No established target; compare with baseline photographs Safety check: new pigmentation prompts stopping
FSFI-D (women) Increase of at least 1.2 points from baseline Primary desire marker
FSDS-DAO item 13 (women) Decrease of at least 1 point from baseline Distress about low desire
IIEF erectile function domain (men) 26–30 Erectile marker in men
Liver enzymes (ALT, AST) Within the reporting laboratory's limits Safety check: marked elevation stops use

Cadence: Blood pressure 2–4 hours after each of the first two doses, then every 3 months; questionnaires at 4 and 8 weeks, with the 8-week result deciding continuation; skin review monthly for 3 months, then every 6 months; liver enzymes at 3 months, then every 6–12 months for frequent users; pregnancy testing whenever pregnancy is suspected.

Qualitative Assessment

  • Desire and initiation: Frequency of spontaneous sexual thoughts and of initiating intimacy
  • Satisfaction: Whether encounters feel more satisfying
  • Side-effect diary: Nausea duration, flushing and headache after each dose
  • Relationship quality: Communication and closeness with a partner
  • Skin changes: New freckles, darkened moles or gum discoloration
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.